All In Biotech

Drug Trial Radar · NCT07225569

A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

A Randomized, Double-blind, Placebo-controlled, Phase 2, Dose-finding Study to Investigate the Efficacy and Safety of SAR445399 in Participants With Moderate to Severe Hidradenitis Suppurativa

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 144 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

144

Planned (sponsor's estimate)

Start

Dec 29, 2025

Primary completion

Sep 22, 2027

Study completion Nov 19, 2027

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Nov 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multinational, randomized, double-blind, placebo-controlled, Phase 2, dose finding study to evaluate the efficacy and safety of different doses of SAR445399 in adult participants with moderate to severe hidradenitis suppurativa. The purpose of this study is to assess the efficacy and safety of two doses of SAR445399 compared with placebo in adult participants with moderate to severe hidradenitis suppurativa. The study duration (per participant) will be up to 46 weeks with a total of 16 visits. The treatment duration will be 32 weeks which includes 16-week double-blinded initial treatment period and a 16-week treatment-blinded extension period.

Conditions

  • Hidradenitis Suppurativa

Interventions

  • SAR445399Drug

    Pharmaceutical form: Solution for injection -Route of administration: Injection

  • PlaceboDrug

    Pharmaceutical form: Solution for injection -Route of administration: Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)Time frame: Up to Week 16

Locations

86 sites in 15 countries. Site status is shown where the registry gives one.

  • Scottsdale Clinical Trials- Site Number : 8400006

    Scottsdale, Arizona · Recruiting

  • Carbon Health - North Hollywood - NoHo West- Site Number : 8400017

    North Hollywood, California · Active not recruiting

  • Encore Medical Research of Boynton Beach- Site Number : 8400005

    Boynton Beach, Florida · Recruiting

  • FXM Clinical Research - Fort Lauderdale- Site Number : 8400013

    Fort Lauderdale, Florida · Recruiting

  • Alliance for Multispeciality Research - Fort Myers- Site Number : 8400007

    Fort Myers, Florida · Recruiting

  • Encore Medical Research - Hollywood- Site Number : 8400004

    Hollywood, Florida · Recruiting

  • Fxm Clinical Research/Fax Pharma Clinical Research- Site Number : 8400014

    Miami, Florida · Recruiting

  • Florida International Research Center- Site Number : 8400002

    Miami, Florida · Recruiting

  • Florida Research Center- Site Number : 8400009

    Miami, Florida · Recruiting

  • Advanced Clinical Research Institute- Site Number : 8400021

    Tampa, Florida · Recruiting

  • Cleaver Medical Group Dermatology- Site Number : 8400008

    Cumming, Georgia · Recruiting

  • First Georgia Physician Group- Site Number : 8400033

    Fayetteville, Georgia · Recruiting

  • NorthShore University Health System - Endeavor Health Medical Group - Skokie - Woods Drive- Site Number : 8400019

    Skokie, Illinois · Recruiting

  • Deaconess Clinic - Downtown Fourth Street- Site Number : 8400029

    Evansville, Indiana · Recruiting

  • Dermatology Specialists Research (DS Research) - Kentucky- Site Number : 8400026

    Louisville, Kentucky · Recruiting

  • Beth Israel Deaconess Medical Center - Boston- Site Number : 8400001

    Boston, Massachusetts · Recruiting

  • University Health Dermatology- Site Number : 8400018

    Kansas City, Missouri · Recruiting

  • Equity Medical (LLC)- Site Number : 8400010

    The Bronx, New York · Recruiting

  • Essential Medical Research- Site Number : 8400015

    Tulsa, Oklahoma · Recruiting

  • Elligo Health Research/The Woodlands Dermatology Associates- Site Number : 8400020

    The Woodlands, Texas · Recruiting

  • Virginia Dermatology & Skin Cancer Center- Site Number : 8400024

    Norfolk, Virginia · Recruiting

  • Investigational Site Number : 0320001

    Buenos Aires, Argentina · Recruiting

  • Investigational Site Number : 0320002

    Buenos Aires, Argentina · Recruiting

  • Investigational Site Number : 0320003

    Buenos Aires, Argentina · Recruiting

  • Investigational Site Number : 0360001

    Sydney, New South Wales, Australia · Recruiting

  • Investigational Site Number : 0360003

    Woodville, South Australia, Australia · Recruiting

  • Investigational Site Number : 0360002

    South Perth, Western Australia, Australia · Recruiting

  • Investigational Site Number : 0560002

    Brussels, Belgium · Recruiting

  • Investigational Site Number : 0560001

    Ghent, Belgium · Recruiting

  • Investigational Site Number : 0560004

    Liège, Belgium · Recruiting

  • Hospital Israelita Albert Einstein- Site Number : 0760004

    São Paulo, Brazil · Recruiting

  • Centro de Pesquisas da Clínica IBIS- Site Number : 0760001

    Salvador, Estado de Bahia, Brazil · Recruiting

  • Hospital das Clinicas da UNICAMP- Site Number : 0760002

    Campinas, São Paulo, Brazil · Recruiting

  • Investigational Site Number : 1240016

    Winnipeg, Manitoba, Canada · Recruiting

  • Investigational Site Number : 1240015

    Mississauga, Ontario, Canada · Recruiting

  • Investigational Site Number : 1240001

    Richmond Hill, Ontario, Canada · Recruiting

  • Investigational Site Number : 1240014

    Toronto, Ontario, Canada · Recruiting

  • Investigational Site Number : 1240010

    Montreal, Quebec, Canada · Recruiting

  • Investigational Site Number : 1240002

    Sherbrooke, Quebec, Canada · Recruiting

  • Investigational Site Number : 1240013

    Regina, Saskatchewan, Canada · Recruiting

Showing 40 of 86 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.